Logout
If you want to log out click in LogOut
The Toll-like receptor signaling pathway (TLR) is a central component of the innate immune system, responsible for the early detection of pathogens and initiation of host defense responses.
Toll-like receptors are pattern recognition receptors (PRRs) that detect pathogen-associated molecular patterns (PAMPs) derived from bacteria, viruses, fungi, and parasites, as well as damage-associated molecular patterns (DAMPs) released from stressed or injured cells.
Upon activation, TLR signaling triggers intracellular cascades that lead to inflammatory cytokine production, type I interferon responses, and activation of adaptive immunity. Dysregulation of this pathway is strongly associated with infectious diseases, chronic inflammation, autoimmune disorders, and cancer.
TLR pathway activity can be efficiently assessed through targeted gene expression analysis of receptors, adaptor proteins, and downstream transcriptional targets.
Toll-like receptor signaling pathway biomarker list
View the genes and molecular targets included in our TLR pathway qPCR arrays.
Toll-like receptors are classified according to their cellular localization and ligand specificity.
Located on the plasma membrane, these receptors primarily detect microbial membrane components:
Located in endosomes, these receptors detect nucleic acids from pathogens:
This spatial organization ensures accurate discrimination between self and non-self nucleic acids.
TLR activation triggers two major intracellular signaling pathways:
Together, these pathways orchestrate balanced inflammatory and antiviral immune responses.
The Toll-like receptor signaling pathway regulates essential immune functions:
Infectious diseases
Defective or excessive TLR signaling affects pathogen clearance and disease severity.
Chronic inflammatory and autoimmune diseases
Persistent TLR activation contributes to:
Cancer
Aberrant TLR signaling influences:
Understanding TLR signaling is therefore critical for immunology and translational research.
TLR signaling represents an important therapeutic target:
At AnyGenes®, we provide high-performance qPCR arrays and customizable SignArrays® designed for Toll-like receptor signaling pathway analysis and biomarker discovery.
Our solutions enable researchers to:
What can be analyzed?
Available solutions
Scientific data is only as powerful as the analysis behind it.
AnyGenes® provides a dedicated data analysis tool specifically developed for SignArrays® pathway panels.
What does it allow you to do?
Developed on Excel (compatible with 2007+), the software is user-friendly and requires no advanced bioinformatics skills.
Customize your own signaling pathways (SignArrays®) with the factors of your choice!
Simply download and complete our Personalized SignArrays® information file
and send it at
[email protected]
to initiate your project.
The TLR signaling pathway detects microbial and danger signals and initiates innate immune responses, inflammation, and antiviral defenses.
TLRs activate MyD88-dependent and TRIF-dependent signaling pathways leading to NF-κB and interferon responses.
NF-κB dysregulation is linked to chronic inflammatory diseases, cancer, cardiovascular disorders, and neurodegenerative diseases.
TLR activation enhances antigen presentation and cytokine production, promoting T- and B-cell activation.
By measuring expression of receptors, adaptor proteins, and downstream target genes using targeted qPCR pathway arrays.
| Signaling Pathways | Product ref | Informations |
|---|---|---|
Toll-Like Receptors | TLR1H1 |
| Signaling Pathways | Product ref | Informations |
|---|---|---|
Toll-Like Receptors | TLR1M1 |
| Signaling Pathways | Product ref | Informations |
|---|---|---|
Toll-Like Receptors | ******* |
Biomarker list in progress. |
| Signaling Pathways | Product ref | Informations |
|---|---|---|
Toll-Like Receptors | ******* |
Biomarker list in progress. |
Looking for more answers? Visit our Help & FAQ section to find detailed informations about our products, services, and technical support.
1. Anwar, M. A et al. Recent clinical trends in Toll-like receptor targeting therapeutics. Medicinal research reviews, (2019) 39(3), 1053–1090.
2. Luo L et al. Signalling, sorting and scaffolding adaptors for Toll-like receptors. J Cell Sci. (2019) 30;133(5).
3. Shi, S et al. Expression profile of Toll‑like receptors in human breast cancer. Molecular medicine reports. (2020) 21(2):786-794.
4. Mokhtari Y et al. Toll-like receptors (TLRs): An old family of immune receptors with a new face in cancer pathogenesis. J Cell Mol Med. (2020) 25(2):639-651.
5. Setrerrahmane S & Xu H. Tumor-related interleukins: old validated targets for new anti-cancer drug development. Mol Cancer. (2017) 19;16(1):153.
6. Ou T et al. The Pathologic Role of Toll-Like Receptor 4 in Prostate Cancer. Front Immunol. (2018) 6;9:1188.